--- title: "Adial Pharmaceuticals: Buy Rating Reiterated as AD04’s Precision AUD Strategy Advances; $8 Price Target Maintained" type: "News" locale: "en" url: "https://longbridge.com/en/news/286301632.md" description: "Analyst Jason McCarthy of Maxim Group has reiterated a Buy rating on Adial Pharmaceuticals, maintaining an $8 price target. He highlights the potential of AD04’s precision strategy for alcohol use disorder, which targets patients unresponsive to current therapies. The recent submission of AD04 to the FDA’s pilot program could expedite regulatory review. Despite funding challenges, McCarthy sees an attractive risk-reward profile. ADIL’s stock has surged 320.73% over the past six months, rising from $0.328 to $1.380." datetime: "2026-05-13T18:15:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286301632.md) - [en](https://longbridge.com/en/news/286301632.md) - [zh-HK](https://longbridge.com/zh-HK/news/286301632.md) --- # Adial Pharmaceuticals: Buy Rating Reiterated as AD04’s Precision AUD Strategy Advances; $8 Price Target Maintained Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Adial Pharmaceuticals, retaining the price target of $8.00. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Jason McCarthy has given his Buy rating due to a combination of factors tied to Adial’s clinical and regulatory positioning, despite near‑term funding needs. He points to AD04’s genetically targeted strategy for alcohol use disorder, which addresses a specific subset of patients who respond poorly to existing therapies, and sees this precision approach as a key driver of potential clinical and commercial upside. McCarthy also cites the recent submission of AD04 to the FDA’s Commissioner’s National Priority Voucher pilot program, which, if granted, could compress regulatory review to a fraction of the standard timeline and accelerate time to market. Combined with a more flexible FDA stance that may allow approval on a single robust Phase 3 study plus supportive data, and an unchanged $8 price target, he believes the risk‑reward profile remains attractive even as the company works to secure Phase 3 financing and potential partnership support. ADIL’s price has also changed dramatically for the past six months – from $0.328 to $1.380, which is a 320.73% increase. ### Related Stocks - [ADIL.US](https://longbridge.com/en/quote/ADIL.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) ## Related News & Research - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md) - [](https://longbridge.com/en/news/286807703.md) - [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md) - [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)